5/7
08:14 am
ibrx
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® [Yahoo! Finance]
Low
Report
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® [Yahoo! Finance]
5/7
08:00 am
ibrx
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
Medium
Report
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
5/3
05:07 am
ibrx
ImmunityBio partners with Serum Institute for BCG vaccines [Yahoo! Finance]
Medium
Report
ImmunityBio partners with Serum Institute for BCG vaccines [Yahoo! Finance]
5/2
04:13 pm
ibrx
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types [Yahoo! Finance]
Low
Report
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types [Yahoo! Finance]
5/2
04:04 pm
ibrx
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
Low
Report
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
4/30
08:21 am
ibrx
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association [Yahoo! Finance]
Medium
Report
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association [Yahoo! Finance]
4/30
08:00 am
ibrx
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
High
Report
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
4/29
08:03 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its price target raised by analysts at Piper Sandler from $5.00 to $6.00. They now have a "neutral" rating on the stock.
High
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its price target raised by analysts at Piper Sandler from $5.00 to $6.00. They now have a "neutral" rating on the stock.
4/25
07:53 am
ibrx
ImmunityBio immunotherapy shows positive overall survival in lung cancer trial [Seeking Alpha]
Low
Report
ImmunityBio immunotherapy shows positive overall survival in lung cancer trial [Seeking Alpha]
4/25
12:13 am
ibrx
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer [Yahoo! Finance]
Medium
Report
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer [Yahoo! Finance]
4/25
12:03 am
ibrx
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
Medium
Report
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
4/23
06:17 pm
ibrx
Details of 'LA Times Stream' to be revealed this week: Owner [Yahoo! Finance]
High
Report
Details of 'LA Times Stream' to be revealed this week: Owner [Yahoo! Finance]
4/23
05:27 pm
ibrx
ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains [Seeking Alpha]
High
Report
ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains [Seeking Alpha]
4/23
05:05 pm
ibrx
ImmunityBio's bladder cancer therapy wins FDA approval [Yahoo! Finance]
High
Report
ImmunityBio's bladder cancer therapy wins FDA approval [Yahoo! Finance]
4/23
12:52 pm
ibrx
ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications [Seeking Alpha]
Low
Report
ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications [Seeking Alpha]
4/23
12:17 pm
ibrx
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle [Seeking Alpha]
Low
Report
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle [Seeking Alpha]
4/23
12:00 pm
ibrx
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies [Yahoo! Finance]
Low
Report
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies [Yahoo! Finance]
4/23
11:26 am
ibrx
CNN values your feedback [CNN]
Medium
Report
CNN values your feedback [CNN]
4/23
06:00 am
ibrx
ImmunityBio stock jumps as FDA clears bladder cancer therapy [Seeking Alpha]
High
Report
ImmunityBio stock jumps as FDA clears bladder cancer therapy [Seeking Alpha]
4/23
12:40 am
ibrx
FDA approves bladder cancer treatment by Culver City company [Los Angeles Times (CA)]
Medium
Report
FDA approves bladder cancer treatment by Culver City company [Los Angeles Times (CA)]
4/22
10:08 pm
ibrx
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer [Yahoo! Finance]
Medium
Report
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer [Yahoo! Finance]
4/22
09:56 pm
ibrx
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Medium
Report
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
4/22
06:54 pm
ibrx
UPDATE 1-U.S. FDA approves ImmunityBio's bladder cancer therapy [Yahoo! Finance]
Medium
Report
UPDATE 1-U.S. FDA approves ImmunityBio's bladder cancer therapy [Yahoo! Finance]
4/22
06:42 pm
ibrx
U.S. FDA approves ImmunityBio's bladder cancer therapy [Reuters]
Medium
Report
U.S. FDA approves ImmunityBio's bladder cancer therapy [Reuters]
3/25
08:07 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its price target raised by analysts at Piper Sandler from $4.00 to $5.00. They now have a "neutral" rating on the stock.
High
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its price target raised by analysts at Piper Sandler from $4.00 to $5.00. They now have a "neutral" rating on the stock.